Vector-borne diseases (VBDs) represent a significant public health challenge in India, contributing significantly to the country's disease burden. With a diverse range of vectors and climatic conditions conducive to their spread, understanding the extent of this issue is critical for healthcare professionals.
VBDs in India encompass a wide range of illnesses, including malaria, dengue, chikungunya, Japanese encephalitis, and lymphatic filariasis. Each of these diseases presents unique challenges in terms of prevention, diagnosis, and treatment, necessitating a comprehensive understanding of their epidemiology and clinical manifestations.
The epidemiology of VBDs in India is complex, influenced by factors like vector ecology, climate, and socio-economic determinants. Malaria alone accounts for a significant proportion of the disease burden, with an estimated 219 million cases globally in 2017, of which India contributed 4%. Additionally, the country reports the highest dengue burden in the world, with an estimated 100 million cases annually.
The management of VBDs in India faces numerous challenges, including inadequate surveillance, limited resources for vector control, and gaps in public awareness. However, opportunities exist in the form of advancements in diagnostic technologies, vaccine development, and integrated vector management strategies. The role of healthcare professionals is pivotal in leveraging these opportunities to mitigate the VBD burden.
Vector-borne diseases pose a significant public health challenge in India, requiring a comprehensive, multi-faceted approach. Healthcare professionals play a crucial role in this endeavor, from enhancing disease surveillance and diagnosis to driving public education efforts. By deepening our understanding of these diseases and their management, we can work towards reducing their impact on India's health landscape.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation